AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 35 patents, Dr. Deisher leads a team of scientists in researching game-changing stem cell technologies. Our lead molecule, AVM0703, received FDA approval in April 2020 to proceed with Phase I/II clinical trials for the treatment of lymphoid malignancies. AVM Biotechnology’s research shows that AVM0703 may also be an effective therapeutic treatment against viruses, including COVID-19. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for the approval to proceed with clinical trials against this deadly virus.